Krebs Biochemicals & Industries Share Price Today | Stock Price & Krebs Biochemicals & Industries Share Screener
As of October 5, 2026, the live Krebs Biochemicals & Industries share price (NSE: KREBSBIO) is ₹63.96 on NSE and ₹63.95 on BSE, down 6.01% from the previous close, with shares trading between ₹62.20 and ₹67.00 in today's trading session, and a 52-week range of ₹39.75–₹71.28. Check KREBSBIO yearly price range for the annual price range and momentum. Use the Krebs Biochemicals & Industries stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Krebs Biochemicals & Industries opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹27 and net income of ₹-14, an operating margin of -16.0% and a profit margin of -51.9%.
Krebs Biochemicals & Industries Share Price Chart
Track the current stock price of Krebs Biochemicals & Industries with an interactive chart. Analyse KREBSBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Krebs Biochemicals & Industries stock quote in one place.
The quote of ₹63.96 sits between the 52-week low of ₹39.75 and the 52-week high of ₹71.28, and the latest session moved -6.01% from the previous close.
Krebs Biochemicals & Industries Company Profile - Fundamental Screener
Screen Krebs Biochemicals & Industries company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KREBSBIO shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE268B01013.
Company Details
Classification
Identifiers and Leadership
Krebs Biochemicals & Industries Balance Sheet Screener
Screen KREBSBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹163, down from ₹169 in 2025.
Latest statistics put total assets at ₹163 and shareholder funds at ₹-163.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 163 | 169 | 178 | 175 | 190 | 159 | 134 | 142 | 126 | 122 |
| Current Assets | 10 | 10 | 17 | 16 | 36 | 21 | 19 | 31 | 17 | 13 |
| Fixed Assets | 142 | 146 | 150 | 147 | 139 | 118 | 105 | 101 | 101 | 102 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 213 | 212 | 236 | 225 | 187 | 154 | 116 | 102 | 101 | 89 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | -163 | -146 | -119 | -100 | -75 | -43 | -25 | -14 | -18 | 2 |
| Share Capital | 22 | 22 | 22 | 22 | 22 | 20 | 18 | 17 | 14 | 14 |
| Reserves & Surplus | -184 | -168 | -141 | -121 | -97 | -67 | -43 | -31 | -32 | -12 |
Krebs Biochemicals & Industries Income Statement Screener - Profit & Revenue Analysis
Screen Krebs Biochemicals & Industries income statement and profit fundamentals. Analyze KREBSBIO quarterly results. Krebs Biochemicals & Industries reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹27 and net profit was ₹-14, equal to earnings per unit of ₹-6.50, at an operating margin of -16%.
In that period expenses were ₹28, interest cost ₹7 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹26 and net profit of ₹-17.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 27 | 26 | 44 | 51 | 53 | 61 | 54 | 34 | 48 | 34 | 3 | 2 | 0 |
| Expenses | 28 | 29 | 58 | 59 | 68 | 94 | 71 | 52 | 58 | 41 | 11 | 14 | 5 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 0 | -3 | -14 | -8 | -15 | -33 | -17 | -18 | -10 | -7 | -8 | -11 | -5 |
| Operating Profit % | -16.00% | -23.00% | -35.00% | -17.00% | -30.00% | -57.00% | -33.00% | -56.00% | -21.00% | -22.00% | -246.00% | -962.00% | 0.00% |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 6 | 5 | 5 | 4 | 4 | 4 | 5 | 2 |
| Interest | 7 | 7 | 6 | 5 | 3 | 5 | 6 | 6 | 6 | 5 | 4 | 1 | 4 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | -14 | -17 | -27 | -20 | -25 | -45 | -28 | -29 | -20 | -18 | -16 | -16 | -8 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -14 | -17 | -27 | -20 | -25 | -45 | -28 | -29 | -20 | -18 | -16 | -16 | -8 |
| EPS | -6.50 | -7.85 | -12.49 | -9.15 | -11.30 | -20.81 | -14.37 | -17.90 | -12.83 | -12.97 | -11.68 | -12.49 | -8.24 |
Krebs Biochemicals & Industries Cash Flow Screener - Liquidity Fundamentals
Screen KREBSBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹2.
Over the same period, investing activities used ₹4 and financing activities provided ₹6.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -2 | -8 | 2 | -25 | -17 | -15 | -36 | 4 | -6 | -11 |
| Investing Activities | -4 | -5 | -8 | -13 | -23 | -23 | -10 | -4 | -3 | -5 |
Financing and Net Cash | ||||||||||
| Financing Activities | 6 | 13 | 6 | 37 | 40 | 38 | 29 | 17 | 9 | 16 |
| Net Cash Flow | 0 | 0 | 0 | 0 | -1 | 1 | -17 | 17 | 0 | 0 |
Krebs Biochemicals & Industries Shareholding Pattern Screener
See Krebs Biochemicals & Industries shareholding pattern with promoter, FII, and DII holdings. Check Krebs Biochemicals & Industries promoter holding and ownership changes for KREBSBIO on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 72.74%, foreign institutions 0.50%, domestic institutions 0.00% and the public 19.81%, spread across 8,553 shareholders.
The shareholder count was 8,553 in 2026-Mar, compared with 8,521 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% |
Institutional Investors | ||||||||
| FII Holding | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.00% | 0.50% | 0.50% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 19.81% | 19.67% | 20.42% | 19.73% | 19.70% | 19.80% | 20.11% | 19.97% |
| Other Holding | 6.95% | 7.09% | 6.34% | 7.03% | 7.06% | 7.46% | 6.65% | 6.79% |
| Shareholder Count | 8,553 | 8,521 | 8,798 | 9,118 | 8,912 | 8,710 | 8,909 | 8,848 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Krebs Biochemicals & Industries. Krebs Biochemicals & Industries dividend yield can be compared with peers and other stocks in the market.
Krebs Biochemicals & Industries Stock Index Membership - Nifty & Sensex
See which indices include Krebs Biochemicals & Industries stock. Check KREBSBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Krebs Biochemicals & Industries Market Events Screener - Corporate Actions
Get Krebs Biochemicals & Industries corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Krebs Biochemicals & Industries stock events that may affect KREBSBIO share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Annual General Meeting dated September 29, 2026, with a record date of September 29, 2026.
It is followed by Quarterly Result Announcement dated August 6, 2026 and Quarterly Result Announcement dated May 21, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-29 | 2026-09-29 | Annual General Meeting | NA | 8.42% |
| 2026-08-06 | 2026-08-06 | Quarterly Result Announcement | NA | -3.07% |
| 2026-05-21 | 2026-05-21 | Quarterly Result Announcement | NA | -9.59% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | -9.74% |
| 2025-11-04 | 2025-11-04 | Quarterly Result Announcement | NA | -2.74% |
| 2025-09-26 | 2025-09-26 | Annual General Meeting | NA | 0.87% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -3.19% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 6.47% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | 7.47% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 19.68% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -0.51% |
| 2019-01-31 | 2019-02-01 | Rights | 21:100 | -6.90% |
Krebs Biochemicals & Industries Competitors Screener - Peer Stocks Comparison
Screen KREBSBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Krebs Biochemicals & Industries Company Announcements - News & Reports Screener
Screen KREBSBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated October 1, 2026 and September 21, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-21 | Closure of Trading Window | - |
| 2026-09-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Notice Of 34Th Annual General Meeting Of The Company | - |
| 2026-09-04 | Reg. 34 (1) Annual Report. | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-06 | Results | - |
| 2026-08-06 | Board Meeting Outcome for Outcome Of BM | - |
| 2026-07-28 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 6Th Agust 2026 | - |
| 2026-07-02 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-26 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
| 2026-06-26 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-06-22 | Closure of Trading Window | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-21 | Result For FY Ended 31.03.2026 | - |
| 2026-05-21 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-05-07 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹63.96, within a 52-week range of ₹39.75 to ₹71.28. The P/E ratio is -9.22 and the P/B ratio is -0.80, with earnings per unit of ₹-7.85. Market capitalisation stands at ₹146.72 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.